Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA)

Q: What does CUSIP 152309100 represent in this 13F holders report?

CUSIP 152309100 is the security identifier for CNTA - Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share used to aggregate holder disclosures.

Q: How many institutions held CNTA - Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share in Q4 2021?

46 institutional investors reported CNTA - Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share for Q4 2021. Use the holders table for investor-level position and value details.

CUSIP: 152309100

Q4 2021 13F Holders as of 31 Dec 2021

Type / Class: Equity / Ordinary shares, nominal value 0.002 GBP per share
Shares outstanding: 145,993,531
Total 13F shares: 71,873,880
Share change: +2,015,902
Total reported value: $807,766,000
Price per share: $11.26
Number of holders: 46
Value change: +$18,577,946
Number of buys: 29
Number of sells: 15

Quarterly Holders Quick Answers

What is CUSIP 152309100?
CUSIP 152309100 identifies CNTA - Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2022
Previous quarter: Q3 2021

Recent filing periods for CUSIP 152309100:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of CNTA - Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Medicxi Ventures Management (Jersey) Ltd	13F	Company	12%	17,923,892	$299,329,000	—	30 Sep 2021	13F
GENERAL ATLANTIC, L.P.	13F	Individual	6.6%	9,681,818	$161,686,000	—	30 Sep 2021	13F
JANUS HENDERSON GROUP PLC	13F	Company	3.8%	5,607,302	$91,362,000	—	30 Sep 2021	13F
RA CAPITAL MANAGEMENT, L.P.	13F	Company	2.5%	3,577,094	$59,737,000	—	30 Sep 2021	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	1.4%	2,017,873	$33,091,000	—	30 Sep 2021	13F
Cormorant Asset Management, LP	13F	Company	1.2%	1,727,273	$28,724,000	—	30 Sep 2021	13F
Samsara BioCapital, LLC	13F	Company	1.1%	1,537,533	$25,677,000	—	30 Sep 2021	13F
Boxer Capital, LLC	13F	Company	0.91%	1,334,227	$22,282,000	—	30 Sep 2021	13F
BAKER BROS. ADVISORS LP	13F	Company	0.77%	1,127,273	$18,825,000	—	30 Sep 2021	13F
VR Adviser, LLC	13F	Company	0.77%	1,127,272	$18,825,000	—	30 Sep 2021	13F
Logos Global Management LP	13F	Company	0.73%	1,069,545	$17,861,000	—	30 Sep 2021	13F
DRIEHAUS CAPITAL MANAGEMENT LLC	13F	Company	0.7%	1,018,800	$17,014,000	—	30 Sep 2021	13F
FRANKLIN RESOURCES INC	13F	Company	0.63%	922,100	$15,399,000	—	30 Sep 2021	13F
Woodline Partners LP	13F	Company	0.6%	882,813	$14,743,000	—	30 Sep 2021	13F
EcoR1 Capital, LLC	13F	Company	0.52%	754,545	$12,601,000	—	30 Sep 2021	13F
AMERICAN CENTURY COMPANIES INC	13F	Company	0.25%	370,292	$6,184,000	—	30 Sep 2021	13F
FMR LLC	13F	Company	0.25%	362,737	$6,058,000	—	30 Sep 2021	13F
CITADEL ADVISORS LLC	13F	Company	0.24%	349,548	$5,837,000	—	30 Sep 2021	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.23%	337,002	$5,628,000	—	30 Sep 2021	13F
Point72 Asset Management, L.P.	13F	Company	0.21%	302,200	$5,047,000	—	30 Sep 2021	13F
JENNISON ASSOCIATES LLC	13F	Company	0.2%	296,456	$4,951,000	—	30 Sep 2021	13F
Ensign Peak Advisors, Inc	13F	Company	0.2%	286,404	$4,783,000	—	30 Sep 2021	13F
Affinity Asset Advisors, LLC	13F	Company	0.14%	203,183	$3,393,000	—	30 Sep 2021	13F
INDEX VENTURES LIFE VI (JERSEY) L.P.	3/4/5	10%+ Owner	— class O/S missing	149,421	$1,189,391	—	27 May 2021	3/4/5
CAAS CAPITAL MANAGEMENT LP	13F	Company	0.04%	62,500	$1,044,000	—	30 Sep 2021	13F
TD ASSET MANAGEMENT INC	13F	Company	0.02%	33,252	$555,000	—	30 Sep 2021	13F
Aaron Kantoff	3/4/5	Director	— class O/S missing	60,000	$477,600	—	18 Nov 2021	3/4/5
BROOKFIELD Corp /ON/	13F	Company	0.02%	26,788	$447,000	—	30 Sep 2021	13F
Ghisallo Capital Management LLC	13F	Company	0.01%	15,000	$251,000	—	30 Sep 2021	13F
D. E. Shaw & Co., Inc.	13F	Company	0.01%	12,420	$207,000	—	30 Sep 2021	13F
MORGAN STANLEY	13F	Company	0.01%	7,630	$128,000	—	30 Sep 2021	13F
Vida Ventures Advisors, LLC	13F	Company	2.7%	3,931,818	$65,661	—	30 Sep 2021	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	2,771	$46,000	—	30 Sep 2021	13F
Lombard Odier SCmA Compagnie	13F	Individual	0%	2,750	$46,000	—	30 Sep 2021	13F
JPMORGAN CHASE & CO	13F	Company	0%	1,828	$30,000	—	30 Sep 2021	13F
ROYAL BANK OF CANADA	13F	Company	0%	453	$8,000	—	30 Sep 2021	13F
UBS Group AG	13F	Company	0%	221	$4,000	—	30 Sep 2021	13F
CITIGROUP INC	13F	Company	0%	209	$3,000	—	30 Sep 2021	13F
Cubist Systematic Strategies, LLC	13F	Company	0%	200	$3,000	—	30 Sep 2021	13F
Evolution Wealth Advisors, LLC	13F	Company	0%	160	$3,000	—	30 Sep 2021	13F
Tower Research Capital LLC (TRC)	13F	Company	0%	119	$2,000	—	30 Sep 2021	13F

Institutional Holders of Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA) as of Q4 2021

As of 31 Dec 2021, Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA) was held by 46 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 71,873,880 shares. The largest 10 holders included Medicxi Ventures Management (Jersey) Ltd, Index Venture Life Associates VI Ltd, GENERAL ATLANTIC, L.P., JANUS HENDERSON GROUP PLC, Vida Ventures Advisors, LLC, RA CAPITAL MANAGEMENT, L.P., Cormorant Asset Management, LP, OUP Management Co., LLC, PRICE T ROWE ASSOCIATES INC /MD/, and Samsara BioCapital, LLC. This page lists 46 institutional shareholders reporting positions in this security for the Q4 2021 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2021 vs Q3 2021 Across Filers

Q3 2021 holders

Q4 2021 holders

Holder diff

Investor	Q3 2021 Shares	Q4 2021 Shares	Share Diff	Share Chg %	Q3 2021 Value $	Q4 2021 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.